{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T02:35:17Z","timestamp":1772505317789,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tertiary outpatient ophthalmology clinics are high-risk environments for COVID-19 transmission, especially retina clinics, where regular follow-up is needed for elderly patients with multiple comorbidities. Intravitreal injection therapy (IVT) for chronic macular diseases, is one of the most common procedures performed, associated with a significant burden of care because of the vigorous treatment regimen associated with multiple investigations. While minimizing the risk of COVID-19 infection transmission is a priority, this must be balanced against the continued provision of sight-saving ophthalmic care to patients at risk of permanent vision loss. This review aims to give evidence-based guidelines on managing IVT during the COVID-19 pandemic in common macular diseases such as age-related macular degeneration, diabetic macula edema and retinal vascular disease and to report on how the COVID-19 pandemic has affected IVT practices worldwide.<\/jats:p><jats:p>To illustrate some real-world examples, 18 participants in the International Retina Collaborative, from 15 countries and across four continents, were surveyed regarding pre- and during- COVID-19 pandemic IVT practices in tertiary ophthalmic centers. The majority of centers reported a reduction in the number of appointments to reduce the risk of the spread of COVID-19 with varying changes to their IVT regimen to treat various macula diseases. Due to the constantly evolving nature of the COVID-19 pandemic, and the uncertainty about the normal resumption of health services, we suggest that new solutions for eye healthcare provision, like telemedicine, may be adopted in the future when we consider new long-term adaptations required to cope with the COVID-19 pandemic.<\/jats:p>","DOI":"10.1186\/s40942-022-00380-6","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T09:03:22Z","timestamp":1654592602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Are intravitreal injections essential during the COVID-19 pandemic? Global preferred practice patterns and practical recommendations"],"prefix":"10.1186","volume":"8","author":[{"given":"A. C. S.","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Anaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Chatziralli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. V.","family":"Cicinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Faes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mustapha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Phasukkijwatana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Pohlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rosenblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Savastano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Touhami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Vaezi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. V.","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ambati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. D.","family":"de Smet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Loewenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the International Retina Collaborative","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"380_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijsu.2020.02.034","volume":"76","author":"C Sohrabi","year":"2020","unstructured":"Sohrabi C, Alsafi Z, O\u2019Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71\u20136. https:\/\/doi.org\/10.1016\/j.ijsu.2020.02.034.","journal-title":"Int J Surg"},{"issue":"5","key":"380_CR2","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00417-020-04641-8","volume":"258","author":"THT Lai","year":"2020","unstructured":"Lai THT, Tang EWH, Chau SKY, Fung KSC, Li KKW. Stepping up infection control measures in ophthalmology during the novel coronavirus outbreak: an experience from Hong Kong. Graefes Arch Clin Exp Ophthalmol. 2020;258(5):1049\u201355. https:\/\/doi.org\/10.1007\/s00417-020-04641-8.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"380_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-04693-w","author":"F Antaki","year":"2020","unstructured":"Antaki F, Dirani A. Treating neovascular age-related macular degeneration in the era of COVID-19. Graefes Arch Clin Exp Ophthalmol. 2020. https:\/\/doi.org\/10.1007\/s00417-020-04693-w.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"380_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OPTH.S151611","volume":"12","author":"C Ehlken","year":"2018","unstructured":"Ehlken C, Helms M, B\u00f6hringer D, Agostini HT, Stahl A. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol. 2018;12:13\u201320. https:\/\/doi.org\/10.2147\/OPTH.S151611.","journal-title":"Clin Ophthalmol"},{"key":"380_CR5","unstructured":"Ophthalmologists RCo. COVID-19 clinical guidance for ophthalmologists. 2020. https:\/\/www.rcophth.ac.uk\/2020\/03\/covid-19-update-and-resources-for-ophthalmologists\/."},{"key":"380_CR6","unstructured":"Ophthalmology AAo. New recommendations for urgent and non-urgent patient care. United States of America. 2020. https:\/\/www.aao.org\/headline\/new-recommendations-urgent-nonurgent-patient-care."},{"key":"380_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-04703-x","author":"JF Korobelnik","year":"2020","unstructured":"Korobelnik JF, Loewenstein A, Eldem B, et al. Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol. 2020. https:\/\/doi.org\/10.1007\/s00417-020-04703-x.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"380_CR8","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","volume":"35","author":"KB Freund","year":"2015","unstructured":"Freund KB, Korobelnik JF, Devenyi R, et al. Treat-and-extend regimens with anti-vegf agents in retinal diseases: a literature review and consensus recommendations. Retina. 2015;35(8):1489\u2013506. https:\/\/doi.org\/10.1097\/IAE.0000000000000627.","journal-title":"Retina"},{"issue":"7","key":"380_CR9","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","volume":"255","author":"P Lanzetta","year":"2017","unstructured":"Lanzetta P, Loewenstein A, Committee VAS. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1259\u201373. https:\/\/doi.org\/10.1007\/s00417-017-3647-4.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10326","key":"380_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1.","journal-title":"Lancet"},{"issue":"10326","key":"380_CR11","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(22)00018-6.","journal-title":"Lancet"},{"issue":"8","key":"380_CR12","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.oret.2020.11.004","volume":"5","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Callanan D, Dreyer R, et al. End-of-study results for the ladder phase 2 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retina. 2021;5(8):775\u201387. https:\/\/doi.org\/10.1016\/j.oret.2020.11.004.","journal-title":"Ophthalmol Retina."},{"issue":"14","key":"380_CR13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331. https:\/\/doi.org\/10.1056\/NEJMoa054481.","journal-title":"N Engl J Med"},{"key":"380_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12886-016-0207-3","volume":"16","author":"JJ Arnold","year":"2016","unstructured":"Arnold JJ, Markey CM, Kurstjens NP, Guymer RH. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration\u2013a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016;16:31. https:\/\/doi.org\/10.1186\/s12886-016-0207-3.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"380_CR15","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1177\/1120672120963448","volume":"31","author":"R Sacconi","year":"2021","unstructured":"Sacconi R, Borrelli E, Vella G, et al. TriPla Regimen: a new treatment approach for patients with neovascular age-related macular degeneration in the COVID-19 \u201cera.\u201d Eur J Ophthalmol. 2021;31(3):849\u201352. https:\/\/doi.org\/10.1177\/1120672120963448.","journal-title":"Eur J Ophthalmol"},{"issue":"10","key":"380_CR16","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","volume":"120","author":"DM Brown","year":"2013","unstructured":"Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013\u201322. https:\/\/doi.org\/10.1016\/j.ophtha.2013.02.034.","journal-title":"Ophthalmology"},{"issue":"3","key":"380_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00417-021-05097-0","volume":"259","author":"JF Korobelnik","year":"2021","unstructured":"Korobelnik JF, Loewenstein A, Eldem B, et al. Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure. Graefes Arch Clin Exp Ophthalmol. 2021;259(3):567\u201374. https:\/\/doi.org\/10.1007\/s00417-021-05097-0.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"380_CR18","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1097\/IAE.0000000000002919","volume":"40","author":"A Hadayer","year":"2020","unstructured":"Hadayer A, Zahavi A, Livny E, et al. Patients wearing face masks during intravitreal injections may be at a higher risk of endophthalmitis. Retina. 2020;40(9):1651\u20136. https:\/\/doi.org\/10.1097\/IAE.0000000000002919.","journal-title":"Retina"},{"issue":"3","key":"380_CR19","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1111\/aos.14945","volume":"100","author":"K Blom","year":"2022","unstructured":"Blom K, Bragad\u00f3ttir R, Sivertsen MS, Moe MC, J\u00f8rstad \u00d8. Mask use by patients in the context of COVID-19 can increase the risk of postinjection endophthalmitis. Acta Ophthalmol. 2022;100(3):e859\u201360. https:\/\/doi.org\/10.1111\/aos.14945.","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"380_CR20","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/j.ophtha.2021.05.010","volume":"128","author":"SN Patel","year":"2021","unstructured":"Patel SN, Tang PH, Storey PP, et al. The influence of Universal face mask use on endophthalmitis risk after intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 2021;128(11):1620\u20136. https:\/\/doi.org\/10.1016\/j.ophtha.2021.05.010.","journal-title":"Ophthalmology"},{"issue":"11","key":"380_CR21","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1097\/IAE.0000000000003202","volume":"41","author":"J Mar\u00edn-Nieto","year":"2021","unstructured":"Mar\u00edn-Nieto J, Reino-Perez C, Santillana-Cernuda G, D\u00edaz-Bernal JM, Luque-Aranda R, Garc\u00eda-Basterra I. Face mask contamination during COVID-19 pandemia a study on patients receiving intravitreal injections. Retina. 2021;41(11):2215\u201320. https:\/\/doi.org\/10.1097\/IAE.0000000000003202.","journal-title":"Retina"},{"issue":"225","key":"380_CR22","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ajo.2021.01.021","volume":"05","author":"WG Schultheis","year":"2021","unstructured":"Schultheis WG, Sharpe JE, Zhang Q, et al. Effect of taping face masks on quantitative particle counts near the eye: implications for intravitreal injections in the COVID-19 Era. Am J Ophthalmol. 2021;05(225):166\u201371. https:\/\/doi.org\/10.1016\/j.ajo.2021.01.021.","journal-title":"Am J Ophthalmol"},{"key":"380_CR23","doi-asserted-by":"publisher","first-page":"251584142110188","DOI":"10.1177\/25158414211018893","volume":"13","author":"M Verolino","year":"2021","unstructured":"Verolino M, Grassi P, Sosto G, D\u2019Onofrio G, De Simone S, Costagliola C. Lean approach to the management of patients undergoing intravitreal injections during COVID-19 pandemic. Ther Adv Ophthalmol. 2021;13:25158414211018892. https:\/\/doi.org\/10.1177\/25158414211018893.","journal-title":"Ther Adv Ophthalmol."},{"issue":"2","key":"380_CR24","doi-asserted-by":"publisher","first-page":"e18810","DOI":"10.2196\/18810","volume":"6","author":"R Ohannessian","year":"2020","unstructured":"Ohannessian R, Duong TA, Odone A. Global telemedicine implementation and integration within health systems to fight the COVID-19 pandemic: a call to action. JMIR Public Health Surveill. 2020;6(2):e18810. https:\/\/doi.org\/10.2196\/18810.","journal-title":"JMIR Public Health Surveill"},{"key":"380_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2020.04.030","author":"WR Smith","year":"2020","unstructured":"Smith WR, Atala AJ, Terlecki RP, Kelly EE, Matthews CA. Implementation guide for rapid integration of an outpatient telemedicine program during the COVID-19 pandemic. J Am Coll Surg. 2020. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2020.04.030.","journal-title":"J Am Coll Surg"},{"key":"380_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/1357633X20960636","author":"J Mintz","year":"2020","unstructured":"Mintz J, Labiste C, DiCaro MV, McElroy E, Alizadeh R, Xu K. Teleophthalmology for age-related macular degeneration during the COVID-19 pandemic and beyond. J Telemed Telecare. 2020. https:\/\/doi.org\/10.1177\/1357633X20960636.","journal-title":"J Telemed Telecare"},{"issue":"3","key":"380_CR27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/bjophthalmol-2019-314161","volume":"104","author":"C Kern","year":"2020","unstructured":"Kern C, Fu DJ, Kortuem K, et al. Implementation of a cloud-based referral platform in ophthalmology: making telemedicine services a reality in eye care. Br J Ophthalmol. 2020;104(3):312\u20137. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314161.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"380_CR28","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/IAE.0000000000002941","volume":"41","author":"F Viola","year":"2021","unstructured":"Viola F, Milella P, Pozzo Giuffrida F, Ganci S, Invernizzi A. Impact of coronavirus disease pandemic on intravitreal injections treatment for macular diseases: report from a referral hospital in Milan. Retina. 2021;41(4):701\u20135. https:\/\/doi.org\/10.1097\/IAE.0000000000002941.","journal-title":"Retina"},{"key":"380_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10153281","author":"C Arruabarrena","year":"2021","unstructured":"Arruabarrena C, Toro MD, Onen M, et al. Impact on visual acuity in neovascular age related macular degeneration (nAMD) in Europe Due to COVID-19 pandemic lockdown. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10153281.","journal-title":"J Clin Med"},{"issue":"2","key":"380_CR30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1001\/jamaophthalmol.2020.5594","volume":"139","author":"S de Billioti Gage","year":"2021","unstructured":"de Billioti Gage S, Drouin J, Desplas D, et al. Intravitreal anti-vascular endothelial growth factor use in france during the coronavirus disease 2019 pandemic. JAMA Ophthalmol. 2021;139(2):240\u20132. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.5594.","journal-title":"JAMA Ophthalmol."},{"key":"380_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05521-5","author":"B Stemplewitz","year":"2022","unstructured":"Stemplewitz B, Luethy J, Eddy MT, et al. Impact of the COVID-19 pandemic\u2019s first wave on the care and treatment situation of intravitreal injections in a German metropolitan region. Graefes Arch Clin Exp Ophthalmol. 2022. https:\/\/doi.org\/10.1007\/s00417-021-05521-5.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"380_CR32","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s00417-020-04955-7","volume":"258","author":"E Borrelli","year":"2020","unstructured":"Borrelli E, Grosso D, Vella G, et al. Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol. 2020;258(12):2621\u20138. https:\/\/doi.org\/10.1007\/s00417-020-04955-7.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"380_CR33","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1007\/s00417-020-04858-7","volume":"258","author":"E Borrelli","year":"2020","unstructured":"Borrelli E, Grosso D, Vella G, et al. Impact of COVID-19 on outpatient visits and intravitreal treatments in a referral retina unit: let\u2019s be ready for a plausible \u201crebound effect.\u201d Graefes Arch Clin Exp Ophthalmol. 2020;258(12):2655\u201360. https:\/\/doi.org\/10.1007\/s00417-020-04858-7.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"380_CR34","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/IAE.0000000000003368","volume":"42","author":"J Zarranz-Ventura","year":"2022","unstructured":"Zarranz-Ventura J, Nguyen V, Creuzot-Garcher C, et al. International impact of the COVID-19 pandemic lockdown on intravitreal therapy outcomes: fight retinal blindness registry. Retina. 2022;42(4):616\u201327. https:\/\/doi.org\/10.1097\/IAE.0000000000003368.","journal-title":"Retina"},{"issue":"12","key":"380_CR35","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1097\/IAE.0000000000003276","volume":"41","author":"RB Rush","year":"2021","unstructured":"Rush RB, Rush SW. Outcomes in patients resuming intravitreal anti-vascular endothelial growth factor therapy following treatment delay during the coronavirus-19 pandemic. Retina. 2021;41(12):2456\u201361. https:\/\/doi.org\/10.1097\/IAE.0000000000003276.","journal-title":"Retina"},{"key":"380_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/11206721211010613","author":"MA Sekeroglu","year":"2021","unstructured":"Sekeroglu MA, Kilinc Hekimsoy H, Horozoglu Ceran T, Doguizi S. Treatment of neovascular age related macular degeneration during COVID-19 pandemic: The short term consequences of unintended lapses. Eur J Ophthalmol. 2021. https:\/\/doi.org\/10.1177\/11206721211010613.","journal-title":"Eur J Ophthalmol"},{"issue":"10","key":"380_CR37","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1038\/s41433-020-01315-x","volume":"35","author":"KYC Teo","year":"2021","unstructured":"Teo KYC, Nguyen V, Barthelmes D, Arnold JJ, Gillies MC, Cheung CMG. Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence. Eye. 2021;35(10):2793\u2013801. https:\/\/doi.org\/10.1038\/s41433-020-01315-x.","journal-title":"Eye"},{"issue":"4","key":"380_CR38","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s12325-022-02045-0","volume":"39","author":"B Jiang","year":"2022","unstructured":"Jiang B, Gao L, Dong S, et al. Correction to: the influence of COVID-19 on the stability of patients with neovascular age-related macular degeneration with different treatment regimens. Adv Ther. 2022;39(4):1611. https:\/\/doi.org\/10.1007\/s12325-022-02045-0.","journal-title":"Adv Ther"},{"issue":"12","key":"380_CR39","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.oret.2020.06.027","volume":"4","author":"F Romano","year":"2020","unstructured":"Romano F, Monteduro D, Airaldi M, et al. Increased number of submacular hemorrhages as a consequence of coronavirus disease 2019 lockdown. Ophthalmol Retina. 2020;4(12):1209\u201310. https:\/\/doi.org\/10.1016\/j.oret.2020.06.027.","journal-title":"Ophthalmol Retina."},{"key":"380_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05505-5","author":"J Hanhart","year":"2022","unstructured":"Hanhart J, Wiener R, Totah H, et al. Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2022. https:\/\/doi.org\/10.1007\/s00417-021-05505-5.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"380_CR41","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00417-021-05174-4","volume":"259","author":"LG Stone","year":"2021","unstructured":"Stone LG, Grinton ME, Talks JS. Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity. Graefes Arch Clin Exp Ophthalmol. 2021;259(7):1773\u201380. https:\/\/doi.org\/10.1007\/s00417-021-05174-4.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"380_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11082097","author":"VP Douglas","year":"2022","unstructured":"Douglas VP, Douglas KAA, Vavvas DG, Miller JW, Miller JB. Short- and Long-term visual outcomes in patients receiving intravitreal injections: the impact of the coronavirus 2019 disease (COVID-19)-related lockdown. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11082097.","journal-title":"J Clin Med"},{"issue":"8","key":"380_CR43","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1097\/IAE.0000000000000940","volume":"36","author":"EY Chew","year":"2016","unstructured":"Chew EY, Clemons TE, Harrington M, et al. Effectiveness of different monitoring modalities in the detection of neovascular age-related macular degeneration: The Home Study, Report Number 3. Retina. 2016;36(8):1542\u20137. https:\/\/doi.org\/10.1097\/IAE.0000000000000940.","journal-title":"Retina"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-022-00380-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-022-00380-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-022-00380-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:05:11Z","timestamp":1659110711000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-022-00380-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["380"],"URL":"https:\/\/doi.org\/10.1186\/s40942-022-00380-6","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"18 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No individual patient data was used and questionnaires were completed by the retinal specialists where agreement\/consent was implied by completion or return of the questionnaire.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors have consented for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no competing interest with the contents of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}